Pro­to­cols: Pri­vate eq­ui­ty buy-in val­ues in­Ven­tiv at $3.8B; Cel­gene de­nies char­i­ty scheme al­le­ga­tions

The CRO in­Ven­tiv Health has bagged a buy-in from Ad­vent Health that val­ues the com­pa­ny at $3.8 bil­lion. Ad­vent now be­comes a co-own­er of the com­pa­ny with Thomas H. Lee Part­ners and in­Ven­tiv will drop its plans for an IPO.

Seat­tle Ge­net­ics and its part­ner Take­da say they hit their pri­ma­ry end­point in a Phase III study of Ad­cetris for pa­tients with cu­ta­neous T-cell lym­phoma. The com­pa­nies called the da­ta “high­ly sta­tis­ti­cal­ly sig­nif­i­cant” in the rate of ob­jec­tive re­spons­es which last­ed at least four months. Seat­tle Ge­net­ics’ share price, though, bare­ly budged.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER